Form 4: Zentalis Pharmaceuticals CEO Julia Eastland Reports Acquisition of Stock and Stock Options

Julia Marie Eastland, CEO and President of Zentalis Pharmaceuticals, reports the acquisition of common stock and stock options.

Summary

• On February 3, 2025, Julia Marie Eastland, CEO and President of Zentalis Pharmaceuticals, acquired 59,388 shares of common stock and stock options.
• The common stock was acquired at a price of $0.
• Following the transaction, Eastland directly owns 87,888 shares of common stock.
• The stock options, with an exercise price of $1.68, also relate to 59,388 shares of common stock.
• These options vest over four years in substantially equal monthly installments.
• The restricted stock units vest in substantially equal annual installments over a two year period following the grant date, subject to continued service with the Issuer.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock and option acquisitions by the CEO. While insider buying can be seen as positive, this appears to be part of a compensation package.

Positives

• The acquisition of shares and options by the CEO could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting schedules for the restricted stock units and stock options are contingent upon the Reporting Person's continued service with the Issuer.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The acquisition of shares and options by the CEO could positively influence shareholder sentiment.

Key Dates

Keywords

Zentalis Pharmaceuticals, Julia Eastland, stock options, common stock, Form 4, acquisition, ZNTL